by Louise Adams | 17 Feb 2025 | Blog
Welcome to Part 2 of our probe into the Lancet paper defining ‘clinical o*esity*.’ If you haven’t read Part 1 you can do so here – it’ll make much more sense. For more than two decades I’ve been wading through the stench-swamp of o*esity research,...
by Louise Adams | 30 Jan 2025 | Blog
Since the 1990’s, the weight loss industry has been pushing to have ‘obesity*’ classified as a disease. This is the Holy Grail for pharmaceutical companies, because disease status opens the door to government and insurance subsidies, ensuring a...
by Louise Adams | 13 Jan 2025 | Blog
I’m back with some sterling examples of how Novo Nordisk genuinely care about human health. If you haven’t already, please read Parts 1 and 2 of Risky Business, for a deep dive into Novo’s clever glow-up of their weight loss drugs as cardiovascular...
by Louise Adams | 6 Jan 2025 | Blog
The current hype about weight loss drugs is inescapable, and media coverage is worryingly – and consistently – uncritical. I recently came across this article on the ABC news website: ‘Doctors weigh societal costs of using obesity drugs to treat obesity...
by Louise Adams | 5 Nov 2024 | Blog
Welcome back to my dissection of the Fast Track Trial paper ‘Symptoms of Depression, Eating Disorders and Depression in Adolescents With Obesity’. This will make much more sense if you read Part 1 first. A heads up – this post contains multiple...
by Louise Adams | 22 Oct 2024 | Blog
Today I’m wading through the Fast Trackers’ JAMA publication, Symptoms of Depression, Eating Disorders and Binge Eating in Adolescents With Obesity. There’s so much going on here that it’s going to be a two-parter. This will make more sense if you’ve...
